Wilke W S, Krall P L, Scheetz R J, Babiak T, Danao T, Mazanec D J, Segal A M, Clough J D
Department of Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Ohio 44195-5028.
Clin Exp Rheumatol. 1991 Nov-Dec;9(6):581-7.
We report a retrospective study of 17 patients with systemic lupus erythematosus who were treated with oral methotrexate given as a mean weekly dose of 8.47 +/- 1.72 mg. Methotrexate treatment resulted in symptomatic improvement in 57% of patients and allowed the reduction of the mean daily dose of prednisone from 16.66 mg initially to 8.99 mg at one year follow-up. Twelve of 17 patients (70.6%) experienced at least one episode of toxicity. Factors which might be associated with toxicity are analyzed. Because of its potential as a corticosteroid-sparing agent, controlled studies of methotrexate for the treatment of systemic lupus erythematosus are indicated.
我们报告了一项对17例系统性红斑狼疮患者的回顾性研究，这些患者接受口服甲氨蝶呤治疗，平均每周剂量为8.47±1.72毫克。甲氨蝶呤治疗使57%的患者症状得到改善，并使泼尼松的平均每日剂量从最初的16.66毫克降至随访一年时的8.99毫克。17例患者中有12例（70.6%）至少经历过一次毒性发作。分析了可能与毒性相关的因素。鉴于甲氨蝶呤作为一种糖皮质激素节省剂的潜力，有必要对其治疗系统性红斑狼疮进行对照研究。
